Endocrinology, Vol 137, 1349-1357, Copyright © 1996 by Endocrine Society

ARTICLES

Cell-specific and regulator-induced promoter usage and messenger ribonucleic acid splicing for parathyroid hormone-related protein

J Southby, LM Murphy, TJ Martin and MT Gillespie
St. Vincent's Institute of Medical Research, St. Vincent's Hospital, Victoria, Australia.

PTH-related protein (PTHrP) is the principle mediator of the syndrome of humoral hypercalcemia of malignancy and has potential paracrine actions on smooth muscle, epithelial cell growth, and placental calcium transport. The human PTHrP gene is complex: a combination of three promoters, one 5' alternative splicing event and alternative 3' splicing, which produces three PTHrP isoforms (139, 141, or 173 amino acids), results in multiple PTHrP messenger RNA (mRNA) species. We employed the RT-PCR technique to identify promoter usage and splicing patterns in a range of human cell lines. Cell line-specific utilization of the promoters and the 3' alternative splicing pathways was detected among bone, breast, kidney, and lung cell lines, although each cell line could potentially produce the three PTHrP isoforms. We also determined whether some of the known regulators of PTHrP differentially modulate promoter usage or splicing patterns. Dexamethasone decreased the abundance of each of the alternative mRNA species. In contrast, epidermal growth factor and transforming growth factor-beta treatment increased the abundance of each PTHrP mRNA species, with particularly marked effects on promoter 1- and promoter 2-initiated transcripts, especially those containing exon VII or VIII. Epidermal growth factor treatment was found to alter PTHrP splicing patterns in a manner consistent with increased transcription from promoters 1 and 2 and stabilization of exon VII- and IX-containing transcripts.

This article has been cited by other articles:

				J. L. Fisher, R. J. Thomas-Mudge, J. Elliott, D. K. Hards, N. A. Sims, J. Slavin, T. J. Martin, and M. T. Gillespie Osteoprotegerin overexpression by breast cancer cells enhances orthotopic and osseous tumor growth and contrasts with that delivered therapeutically. Cancer Res., April 1, 2006; 66(7): 3620 - 3628. [Abstract] [Full Text] [PDF]

				V. Richard, A. Luchin, R. M. Brena, C. Plass, and T. J. Rosol Quantitative Evaluation of Alternative Promoter Usage and 3' Splice Variants for Parathyroid Hormone-related Protein by Real-Time Reverse Transcription-PCR Clin. Chem., August 1, 2003; 49(8): 1398 - 1402. [Full Text] [PDF]

				S.-M. Kakonen, K. S. Selander, J. M. Chirgwin, J. J. Yin, S. Burns, W. A. Rankin, B. G. Grubbs, M. Dallas, Y. Cui, and T. A. Guise Transforming Growth Factor-beta Stimulates Parathyroid Hormone-related Protein and Osteolytic Metastases via Smad and Mitogen-activated Protein Kinase Signaling Pathways J. Biol. Chem., June 28, 2002; 277(27): 24571 - 24578. [Abstract] [Full Text] [PDF]

				R. S. Goomer, K. A. Johnson, D. W. Burton, D. Amiel, T. M. Maris, A. Gurjal, L. J. Deftos, and R. Terkeltaub The Tetrabasic KKKK147-150 Motif Determines Intracrine Regulatory Effects of PTHrP 1-173 on Chondrocyte PPi Metabolism and Matrix Synthesis Endocrinology, December 1, 2000; 141(12): 4613 - 4622. [Abstract] [Full Text] [PDF]

				N. Chikatsu, S. Fukumoto, Y. Takeuchi, M. Suzawa, T. Obara, T. Matsumoto, and T. Fujita Cloning and Characterization of Two Promoters for the Human Calcium-sensing Receptor (CaSR) and Changes of CaSR Expression in Parathyroid Adenomas J. Biol. Chem., March 10, 2000; 275(11): 7553 - 7557. [Abstract] [Full Text] [PDF]

				F. McL. Collier, W. H. Huang, W. R. Holloway, J. M. Hodge, M. T. Gillespie, L. L. Daniels, M. H. Zheng, and G. C. Nicholson Osteoclasts from Human Giant Cell Tumors of Bone Lack Estrogen Receptors Endocrinology, March 1, 1998; 139(3): 1258 - 1267. [Abstract] [Full Text] [PDF]

				T. A. Guise and G. R. Mundy Cancer and Bone Endocr. Rev., February 1, 1998; 19(1): 18 - 54. [Abstract] [Full Text]

				N. Udagawa, N. J. Horwood, J. Elliott, A. Mackay, J. Owens, H. Okamura, M. Kurimoto, T. J. Chambers, T.  J. Martin, and M. T. Gillespie Interleukin-18 (Interferon-gamma -inducing Factor) Is Produced by Osteoblasts and Acts Via Granulocyte/Macrophage Colony-stimulating Factor and Not Via Interferon-gamma to Inhibit Osteoclast Formation J. Exp. Med., March 17, 1997; 185(6): 1005 - 1012. [Abstract] [Full Text] [PDF]